Late Breaker - EULAR 2023 update on imaging of large vessel vasculitis. Ultrasound is now recommended as first line imaging test in all patients with suspected GCA, and axillary arteries should be in the standard examination, Dejaco C et al, Abst#LB0009, #EULAR2023 @RheumNow https://t.co/ya41nJG6qK

2023 @eular_org recommendations for LVV imaging interestingly, the key changes vs 2018 are about PET/CT: - can consider PET/CT for cranial GCA diagnosis - PET/CT (alt MRI) can be used for monitoring - more for when you lose ESR/CRP because of IL-6i #EULAR2023 @RheumNow https://t.co/2DC37CM6gA

2023 update @EULAR recommendations imaging in GCA What's new: 1. US = first line imaging test 2. Axillary arteries should be included in standard examination 3. Alternative imaging FDG-PET or MRI 4. Takayasu: MRI preferred CT or FDG-PET alternatives @Rheumnow #EULAR23 LB0008 https://t.co/rGPfOPX1gI

#EULAR2023 Clinical Highlights. Vasculitis: OP0061 - new US imaging showing vessel inflammation differentiating patients with Behcet’s vs No-BD. OP0304: cohort study showed Benralizumab (IL5 RA) given for eosinophilic asthma also improved BVAS. RCT for EGPA is ongoing @RheumNow https://t.co/7uohfjGk49

#EULAR2023 #POS0222 Post-hoc Analyses of Phase 3 RCT in Rituximab-treated ANCA vasculitis patients only (65% of total) showed more patients met Remission rate & with lower GC Toxicity vs Pred Taper + RTX at 52 weeks, consistent with Trial Main Results @RheumNow https://t.co/BmiujbhQI9

The steroid dosing in SAPHYR (sarilumab in PMR): Bottom two trajectories: sarilumab protocol & actual Top two trajectories: placebo protocol & actual Fascinating that with sarilumab, more PNL only really in play at PNL <3mg/d. Def takes the heat out POS0715 #EULAR2023 @RheumNow https://t.co/aEC8cQaR7O

What do we do with PMR patients with subclinical GCA seen on ultrasound? Well, in these non-blinded cohorts the subclinical GCA pts got more pred. Was it warranted? Hard to say. If we’re going to look for it, let’s try and figure out what it means POS0712 #EULAR2023 @RheumNow https://t.co/KmCcE0Nsu9

I mean, if proteomics is more your jive for GCA, we’ve got that too here at #EULAR2023. Definite potential for phenotyping a disease with diverse outcomes POS0694 @RheumNow https://t.co/tSWpZlUPoE

Very early days, but it’s cool to see transcriptomics in GCA ➡️ in situ spatial profiling ➡️ drug-gene interactions ➡️ new therapeutic targets identified. Only time will tell if they will work, but very cool nevertheless. POS0091 (Mayo, La Jolla, & INSERM) #EULAR2023 @RheumNow https://t.co/n7raIENVOT

Do we use too much PNL in GCA (when not using TCZ)? Could we wean quicker? Salvarini group n=22 26w PNL weaning protocol from GiACTA, but no TCZ 10/26 in relapse free remission at 1y Much less PNL, still some steroid AEs Way of the future for some? POS0728 #EULAR2023 @RheumNow https://t.co/qeZHeCi9vq